2021 ICD-10-CM Code C67.6

Malignant neoplasm of ureteric orifice

Version 2021
Billable Code
MS-DRG Mapping
Neoplasm Malignant Primary

Valid for Submission

C67.6 is a billable diagnosis code used to specify a medical diagnosis of malignant neoplasm of ureteric orifice. The code C67.6 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.

The ICD-10-CM code C67.6 might also be used to specify conditions or terms like malignant tumor of ureteric orifice, neoplasm of ureteric orifice of urinary bladder, primary malignant neoplasm of ureter or primary malignant neoplasm of ureteric orifice of urinary bladder.

The following anatomical sites found in the Table of Neoplasms apply to this code given the correct histological behavior: Neoplasm, neoplastic bladder (urinary) orifice ureteric or Neoplasm, neoplastic ureter, ureteral orifice (bladder) or Neoplasm, neoplastic ureter-bladder (junction) .

ICD-10:C67.6
Short Description:Malignant neoplasm of ureteric orifice
Long Description:Malignant neoplasm of ureteric orifice

Code Classification

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

Convert C67.6 to ICD-9 Code

Table of Neoplasms

The code C67.6 is included in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.

Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.

Neoplasm, neoplastic Malignant
Primary
Malignant
Secondary
CaInSitu Benign Uncertain
Behavior
Unspecified
Behavior
»Neoplasm, neoplastic
  »bladder (urinary)
    »orifice
      »ureteric
C67.6C79.11D09.0D30.3D41.4D49.4
»Neoplasm, neoplastic
  »ureter, ureteral
    »orifice (bladder)
C67.6C79.11D09.0D30.3D41.4D49.4
»Neoplasm, neoplastic
  »ureter-bladder (junction)
C67.6C79.11D09.0D30.3D41.4D49.4

Information for Patients


Bladder Cancer

The bladder is a hollow organ in your lower abdomen that stores urine. Bladder cancer occurs in the lining of the bladder. It is the sixth most common type of cancer in the United States.

Symptoms include

Risk factors for developing bladder cancer include smoking and exposure to certain chemicals in the workplace. People with a family history of bladder cancer or who are older, white, or male have a higher risk.

Treatments for bladder cancer include surgery, radiation therapy, chemotherapy, and biologic therapy. Biologic therapy boosts your body's own ability to fight cancer.

NIH: National Cancer Institute


[Learn More]

Bladder cancer Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply uncontrollably to form a tumor. The bladder is a muscular organ in the lower abdomen that stores urine until it can be removed (excreted) from the body.Bladder cancer may cause blood in the urine, pain during urination, frequent urination, the feeling of needing to urinate without being able to, or lower back pain. Many of these signs and symptoms are nonspecific, which means they may occur in multiple disorders. People who have one or more of these nonspecific health problems often do not have bladder cancer, but another condition such as an infection.The most common type of bladder cancer, called non-muscle invasive bladder cancer (NMIBC), involves cells lining the inside of the bladder. NMIBC generally does not spread to other tissues (metastasize), but it often does recur after it has been treated. The other type, called muscle-invasive bladder cancer (MIBC), involves cells of the muscle wall of the bladder. MIBC generally does metastasize and is often life-threatening.
[Learn More]

Code History

  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016 (First year ICD-10-CM implemented into the HIPAA code set)